It is necessary to note thatActavis'objectives and goals are not predictions of actual functionality. Actual results varies materially fromActavis'current expectations depending upon a genuine number of factors, dangers and uncertainties affectingActavis'business. These elements include, among others, the impact of competitive pricing and products; the timing and success of product launches; difficulties or delays in manufacturing; the pricing and option of alternative party sourced products and components; successful compliance withFDAand additional governmental regulations applicable toActavisand its alternative party manufacturers' services, products and/or businesses; the issue of predicting how theFDAwill interpret applicable Hatch Waxman rules related toActavis'entitlement to marketing exclusivity and the chance that a detrimental interpretation of such guidelines could negatively affectActavis'marketing exclusivity; changes in the laws and regulations, includingMedicareandMedicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed inActavis'periodic public filings with theSecurities and Exchange Commission, including however, not limited toActavis plc'squarterly report on Form 10-Q for the quarter endedSeptember 30, 2014.Traore, M.D., Adama D. Keita, M.D., Michael P. Fay, Ph.D., Sekou F. Traore, Ph.D., Thomas B. Nutman, M.D., and Amy D. Klion, M.D.: A Randomized Trial of Doxycycline for Mansonella perstans Infection The filarial parasite Mansonella perstans is endemic in western and central Africa, with a distribution that overlaps that of Wuchereria bancrofti, Loa loa, and Onchocerca volvulus. Transmitted through the bite of an infected midge , infective M. Perstans larvae develop during the period of a few months into adult worms that reside in the serous cavities and mesentery and retroperitoneal cells. Microfilariae are carried through the bloodstream, and the ones of M.
Next Post: Justin Lessler.